FM6 476
333
Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional OutcomesA. Villers, P. Puech, V. Flamand, G.-P. Haber, M.M. Desai, S. Crouzet, X. Leroy, S. Chopra,
L. Lemaitre, A. Ouzzane, I.S. Gill
We described a novel technique for robotic partial prostatectomy for isolated
anterior prostate cancer. This technique may be an option for highly selected men
with anterior cancers who are not candidates for focal ablative therapy due to the
proximity of the tumor to the external striated sphincter.
343
Je le pansai, Dieu le gueritA. Sood, F. Abdollah, M. Menon
345
Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation TherapyP. Sooriakumaran, T. Nyberg, O. Akre, A. Widmark, F. Hamdy, M. Graefen, S. Carlsson, G. Steineck,
N.P. Wiklund
These data from a large and comprehensive population-based study suggest that
men at high risk of disseminated prostate cancer have significant oncologic benefit
with initial radical treatment of the primary lesion rather than initial androgen
deprivation therapy alone.
352
Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?C.A. Reichard, B.F. Chapin
354
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas DatasetW. Choi, A. Ochoa, D.J. McConkey, M. Aine, M. Höglund, W.Y. Kim, F.X. Real, A.E. Kiltie, I. Milsom,
L. Dyrskjøt, S.P. Lerner
We analyzed the prevalence of the most common genomic alterations in the
bladder cancer molecular subtypes. The results have important implications for our
understanding of bladder cancer etiology and the development of molecular
subtype-specific therapies.
366
Seeking the Molecular Truth in Bladder Cancer: Biology = Genome (Transcriptome) 2P.C. Black
368
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025B. Escudier, R.J. Motzer, P. Sharma, J. Wagstaff, E.R. Plimack, H.J. Hammers, F. Donskov,
H. Gurney, J.A. Sosman, P.G. Zalewski, U. Harmenberg, D.F. McDermott, T.K. Choueiri,
M. Richardet, Y. Tomita, A. Ravaud, J. Doan, H. Zhao, H. Hardy, S. George
Some patients with previously treated advanced renal cell carcinoma who were not
clinically deteriorating and who were subsequently treated with nivolumab beyond
progression had a reduction in tumor burden and improved overall survival versus
patients who were not treated beyond progression, and an acceptable safety profile.
377
RECISTing the Temptation to Prematurely Stop NivolumabM.S. Humeniuk, A.J. Armstrong
379
The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database StudyK.A. Lawson, O. Saarela, R. Abouassaly, S.P. Kim, R.H. Breau, A. Finelli
Widespread variations in the quality of renal cell carcinoma surgical care exist
across hospitals, with poor quality being associated with inferior patient outcomes.
This is captured by the Renal Cancer Quality Score, a composite quality indicator,
supporting its use as a renal cell carcinoma quality benchmarking tool.
387
Improving Quality in Renal Cell Carcinoma Care: Bridging the Gap Between Measurement and MeaningA.Y. Odisho, J.L. Gore
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 3 , S e p t emb e r 2 0 1 7
Urothelial Cancer
Platinum Priorities
Review Article and
Original Articles together
with the Full Length Editorials
Prostate Cancer
Kidney Cancer